Targeted Fluorescent Probes for High-Contrast Cancer Detection: A Revolutionary Approach
Cancer, a pervasive disease affecting countless individuals worldwide, often prompts surgical intervention as a treatment option. Over the years, advancements in surgical techniques and visual imaging tools, such as glowing dyes, have significantly enhanced the precision of these procedures. However, a critical challenge arises from the potential for these probes to activate in healthy tissues, leading to background fluorescence that complicates the surgeon's decision-making process.
Addressing this issue, our research group has developed an innovative solution to make cancer cells glow within the body. In experiments conducted on mice, we introduced a specialized enzyme to tumors and employed a fluorescence probe that only activates in the presence of this enzyme.
Ryosuke Kojima, Associate Professor at the Laboratory of Chemical Biology and Molecular Imaging, University of Tokyo, explains, "Traditional probes often trigger healthy tissue, causing background noise. Our bioorthogonal dye probe, however, remains inactive unless it encounters its engineered enzyme. Through a process of directed evolution, we trained the enzyme to activate the probe strongly enough for use in living animals."
Kojima, alongside Professor Yasuteru Urano and their team, crafted a unique fluorescent probe resistant to activation by natural body enzymes, minimizing unwanted background glow. This probe was paired with a tailored reporter enzyme, designed to switch it on, resulting in fluorescence primarily where the enzyme is delivered. When tested on mice with peritoneal cancer, the engineered enzyme successfully reached the tumors and was followed by the probe, which illuminated as expected.
The implications of this breakthrough are significant. Kojima highlights, "This system enables the detection of minuscule, millimeter-sized tumor lesions with minimal background noise, offering a level of contrast invaluable during surgery. In the immediate future, it could serve as a powerful research tool, and in the long term, it may assist surgeons in more precise tumor removal by clearly identifying cancer cells."
Furthermore, the versatility of this approach is noteworthy. The system can be adapted to various cancer types, as many cancers exhibit corresponding antigens, which are telltale markers of tumor tissue. By replacing the tumor-targeting component (e.g., an antibody or nanobody against a chosen antigen), the same enzyme-probe pair can be redirected to different cancer types.
Looking ahead, this research holds promise for highly targeted drug delivery, where instead of glowing dyes, cancer-fighting drugs could be precisely directed to the sites of need. However, Kojima emphasizes the early stage of development, noting that trials have only been conducted in mice and that significant work remains before human trials can be considered safe.
Source: University of Tokyo
